Aug 2021: Wuxi AppTec immune profiling in drug discovery and CLDN18.2-related tumor models.
Related Content
In this webinar, WuXi AppTec scientists discuss the latest innovative technologies and products in early-stage drug discovery. Viewers will gain...
VIEW RESOURCEGlucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However,...
VIEW RESOURCE